Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial

SIMPLE SUMMARY: Since there is no effective subsequent-line therapy for patients with cisplatin/gemcitabine-refractory advanced biliary tract cancer, there is an urgent need for new treatment options. This phase 1 and 2a study is the first clinical trial reporting the safety and the efficacy of allo...

Descripción completa

Detalles Bibliográficos
Autores principales: Leem, Galam, Jang, Sung-Ill, Cho, Jae-Hee, Jo, Jung Hyun, Lee, Hee Seung, Chung, Moon Jae, Park, Jeong Youp, Bang, Seungmin, Yoo, Da-Kyung, Cheon, Hyo-Cheon, Kim, Jae-Eun, Lim, Kyeong-Pill, Jung, In-Hye, Im, Jung-Min, Chung, Yong-Yoon, Park, Seung Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454779/
https://www.ncbi.nlm.nih.gov/pubmed/36077766
http://dx.doi.org/10.3390/cancers14174229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454779/
https://www.ncbi.nlm.nih.gov/pubmed/36077766
http://dx.doi.org/10.3390/cancers14174229

Ejemplares similares